News
SNCE
5.75
0.00%
0.00
Science 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical Trial
Barchart · 05/02 07:00
Science 37 Holdings Inc: Statement of changes in beneficial ownership of securities
Press release · 03/12 16:02
Science 37 Holdings Inc: Current report
Press release · 03/12 14:02
Craig-Hallum Releases a Hold Rating on Science 37 (SNCE)
TipRanks · 03/12 12:56
Science 37 Merges with eMed, Restructures, and Delists from Nasdaq
TipRanks · 03/12 12:42
Press Release: eMed completes tender offer for all outstanding shares of Science 37
EMed completes tender offer for all outstanding shares of Science 37 Holdings, Inc. At a price of USD 5.75 per share. 4,715,950 shares were validly tendered and not withdrawn in the tender offer. Science 37 will be a wholly-owned subsidiary of eMed.
Dow Jones · 03/12 10:45
Weekly Report: what happened at SNCE last week (0304-0308)?
Weekly Report · 03/11 09:39
Weekly Report: what happened at SNCE last week (0226-0301)?
Weekly Report · 03/04 09:40
Science 37 Holdings Inc <SNCE.OQ> expected to post a loss of $1.23 a share - Earnings Preview
Science 37 Holdings Inc expected to post a loss of $1.23 a share. The company is expected to report a fall in quarterly revenue to $14.048 million from $15.94 million a year ago. The average analyst estimate is for Science 37 Holdings to show a fall of 11.8% in revenue.
Reuters · 03/01 14:05
SCIENCE 37 HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Science 37 Holdings, Inc. - SNCE
Former Attorney General of Louisiana Charles C. Foti, Jr. And the law firm of Kahn Swick & Foti are investigating the proposed sale of Science 37 Holdings, Inc. To eMed, LLC. Science 37 shareholders will receive $5.75 in cash for each share they own. KSF is seeking to determine whether the consideration undervalues the Company.
Barchart · 02/27 14:55
Weekly Report: what happened at SNCE last week (0219-0223)?
Weekly Report · 02/26 09:44
Weekly Report: what happened at SNCE last week (0212-0216)?
Weekly Report · 02/19 09:44
*Science 37 Holdings: Tender Offer Will Expire March 11 >SNCE
Dow Jones · 02/12 12:47
*Science 37 Holdings: EMed, LLC Announced That Its Wholly-Owned Subsidiary, Marlin Merger Sub Corp, Has Commenced a Cash Tender Offer to Purchase All the Outstanding Shrs of Common Stk of Science 37 Holdings, Inc. for a Price of $5.75 Per Shr >SNCE
Dow Jones · 02/12 12:46
Press Release: eMed commences tender offer for Science 37
EMed commences tender offer for Science 37 Holdings, Inc. For a price of $5.75 per share. The tender offer will expire on March 11, 2024. The offer is being made to purchase all the outstanding shares of common stock of Science 37. A successful consummation of the offer will be followed by a merger.
Dow Jones · 02/12 12:45
Weekly Report: what happened at SNCE last week (0205-0209)?
Weekly Report · 02/12 09:41
SCIENCE 37 HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Science 37 Holdings, Inc. - SNCE
Former Attorney General of Louisiana Charles C. Foti, Jr. And the law firm of Kahn Swick & Foti are investigating the proposed sale of Science 37 Holdings, Inc. To eMed, LLC. Science 37 shareholders will receive $5.75 in cash for each share they own. KSF is seeking to determine whether the consideration undervalues the Company.
Barchart · 02/10 10:08
Science 37 Initiates Cost-Cutting, Workforce Reduction Plan
TipRanks · 02/10 09:03
Analysts Offer Insights on Healthcare Companies: aTyr Pharma (LIFE), CVS Health (CVS) and Science 37 (SNCE)
TipRanks · 02/09 13:50
Weekly Report: what happened at SNCE last week (0129-0202)?
Weekly Report · 02/05 09:43
More
Webull provides a variety of real-time SNCE stock news. You can receive the latest news about Science 37 Holdings Inc through multiple platforms. This information may help you make smarter investment decisions.
About SNCE
Science 37 Holdings, Inc. is engaged in patient-centric clinical trials and in supporting novel approaches to decentralized clinical trial designs. Through its patient-centric approach, it reduces the impact of the geographic barriers associated with conventional physical clinical trial sites, enabling recruitment of virtually any patient. Its offerings lie in its configurable unified technology platform combined with its centralized patient recruitment capabilities and specialized network of patient communities. Its unified technology platform is purpose-built for patient-centric clinical trial execution and is designed to provide an end-to-end, single stop solution. It also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, and remote coordinators designed for the purpose of orchestrating patient-centric clinical trials. It uses diversified, multi-channel programs to identify patients who fit the profile for each of its projects.